COVID-RUO Profiling
Power Your Discoveries in a Truly Unparalleled Fashion
Achieve Higher Resolution. Greater Specificity. Unmatched Reproducibility Multiplex Profiling of 14 SARS-CoV-2 Proteins
Ideal For
Long-haul and Longitudinal COVID studies
Analysis of samples for profiles associated with disease severity
(e.g. mild vs. severe)
Distinguishing pathogen cross-over to determine true cases of COVID
Multivariate analysis
Serimmune SERA Technology
Robust and Reproducible
- 96-well throughput, standardized pipelines and established confidence intervals and run standards
Monitors all SARS-CoV-2 proteins with single amino acid resolution across the entire proteome
Multi-target detection performed at one time
State-of-the-Art Reference Database
- Compare any sample relative to our database of thousands of pre-pandemic controls
- Truly disambiguate signal vs. noise
- Reduce false positives
Highly interactive, intuitive and easy-to-understand customer report
Customer Report
A list of 52 motifs identified as sensitive and specific to SARS-CoV-2 positive patients and the related enrichment scores are provided for each sample.
Samples are compared to a pre-pandemic/healthy control, a COVID positive subject cohort and a COVID vaccine recipient cohort. Results are provided in an easy-to-understand and interactive html format.
Raw data that includes Motifs with Enrichment Scores and IWAS values for each amino acid in the SARS-CoV-2 proteome to allow for more in-depth analysis by the customer.
COVID-RUO Profiling Service Sample Report
How it Works
Customer Provides
50 ul of serum or plasma per sample
Minimal information about the samples
Serimmune
Analyzes each sample for IgG antibodies using its 10 billion member, random 12mer, bacterial peptide display library
Performs epitope analysis across the entire SARS-CoV-2 Proteome using its proprietary IMUNE and PIWAS methodologies
Provides summary data and visualizations for each sample, including raw data for subsequent customer analysis
“Due to the flexibility of the SERA platform, we rapidly predicted that the B.1.1.7 variant is unlikely to escape antibodies generated against linear epitopes in prior SARS-CoV-2 infections.
This is the tip of the iceberg for what Serimmune can do. I am excited to continue to collaborate with the team.”
Dr. Akiko Iwasaki
Waldemar Von Zedtwitz Professor of Immunobiology and Molecular, Cellular and Developmental Biology and HHMI Investigator at Yale School of Medicine
Frequently Asked Questions
Results are typically delivered within 2 weeks.
Samples should be shipped frozen on dry ice or at 2-8 Deg on cold packs for overnight delivery.
100 ul is preferred if IgG and IgM are run. 50 ul is acceptable if only IgG is run.
No, samples should not be diluted. We dilute the sample 1:25 in the assay.
No, deactivation of the sample is not required prior to shipping.
An enrichment value is calculated for each peptide epitope that is similar to an antibody titer. The combination of antibody affinity and concentration both contribute to this value.
In precision studies, the CVs for serology panels are generally <10%.
Is Serimmune able to accommodate a request for specific amino acid variants that I want to evaluate?
This is a custom service, but we can look at epitopes against arbitrary strains or variants.
SERA vs. Antibody sequencing
Antibody sequencing does not provide information on the functional targets of the antibody, it only provides the sequence and quantity of antibody species.
Array-based technologies
Array-based technologies and other technologies such as Virscan focus on specific proteomes or meta-proteomes. Because of the random nature of the SERA library, every sample processed can be leveraged for specificity and cross-reactivity analyses. New strains or variants can be analyzed without redesign of the library.
SERA vs. Peptide arrays
Antigen based peptide arrays are limited to the exact linear amino acid sequences contained in the proteome. By contrast, SERA utilizes a random peptide library that can capture linear epitopes as well as non-mapping, conformational epitopes.
SERA vs. Protein arrays
Protein arrays utilize whole proteins that are very expensive to develop and may exhibit lower specificity compared to peptide-based antibody detection.